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S288 Poster Session IIwith markedly reduced risk for GVHD in lethally irradiated mice
(Ophir et al Blood 2010). We now show that these Tcm can also en-
hance engraftment following sublethal TBI (5.5Gy). Thus, while all
13 BALB/c recipients of 107 Nude-B6 BM cells rejected the graft by
day 30, 6/7mice receiving also 5x106 (B6xBALB/c)F1Tcm exhibited
near full chimerism (81611%,. 6 months follow up). Importantly,
chimerism was associated with successful engraftment of donor skin
(. 3 months follow up) in 4/5 chimeras, while 3rd-party unrelated
skin was promptly rejected. When allogeneic B6 Tcm were used,
9/9 mice displayed full donor chimerism and 5/7 maintained donor
skin for over 3 months, without any GVHD symptoms (weight and
overall appearance were the same as that of control mice). Consider-
ing that RIC may be associated with increased relapse rate, it was of
interest to evaluate the GVL reactivity of Tcm. We previously
showed that anti 3rd-party human CTLs eliminate B-CLL and other
lymphoma types by unique TCR independent mechanism. This kill-
ing initiates with ICAM1-LFA1 adhesion, followed by slow apopto-
sis induced by interaction of CD8 on the CTL with MHC-I on the
tumor cell. Initially, we verified that the anti 3rd-party Tcm can also
kill murine A20 lymphoma cells in-vitro (34.8612.1% after 16hrs of
co-incubation). This killing was mediated by apoptosis (AnnexinV
staining of A20 cells increased from 5.262%, to 14.864.5%, p\
0.05). Next, using a model simulating minimal residual disease, we
followed luciferase expressing A20 cells in-vivo, and studied the ef-
fect of adding Tcm to BMT. Thus, lethally irradiated BALB/c
mice were transplanted with 3x106 allogeneic Nude B6 BM and
5000 A20 cells.While all 8 untreated mice died from tumor overload
by day 28, treatment with 5x106 donor type Tcms one day post BMT
led to tumor elimination and overall survival of 100% (7/7) 100 days
post BMT, without any manifestation of GVHD.
Collectively, our data suggest that anti 3rd-party Tcm can provide
a ‘double supportive effect’ by promoting BM engraftment under
RIC, and inducing GVL reactivity, without causing GVHD. Such
cell therapy could be highly attractive for patients with B cell malig-
nancies who might not tolerate aggressive conditioning.371
COMPARATIVE ANALYSIS OF OUTCOMES OF ALLOGENEIC PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION FROM RELATED AND UNRE-
LATED DONORS FOR ACUTE MYELOID LEUKEMIA
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This study compared the results of allogeneic peripheral blood
stem cell transplantation (PBSCT) from unrelated and related do-
nors in 142 consecutive patients with AML. Among these patients,
101 (71.1%) received an HLA-matched related PBSCT and 41
(28.9%) an HLA-matched unrelated PBSCT. High-risk AML was
defined as the presence of adverse cytogenetics or failure to achieve
CR. Among the 41 (28.9%) patients assigned to the high-risk group,
35 (85.4%) patients had failed to achieve CR and 7 patients (17.1%)
had adverse cytogenetics. The cumulative incidence of acute graft-
versus-host disease (GVHD)was 37.6% in the related PBSCTgroup
and 53.7% in the unrelated PBSCT group. The cumulative inci-
dence of extensive chronic GVHD was higher in the unrelated
PBSCT group (19.5%) than in the related PBSCT group (8.9%).
The overall survival (OS) rate at 4 years was 62.465.4% and
53.861.2% and the cumulative incidence of relapse was 24.8%
and 12.2% in the related and unrelated PBSCT groups, respectively.
In a multivariate analysis, unrelated PBSCT was identified as a risk
factor for the development of extensive chronicGVHD (hazard ratio
5 3.019, P-value5 0.027). Among the factors examined, unfavorable
cytogenetics and the disease status at the time of transplantationwere
found to be related with overall survival. In the case of high-risk
AML, the survival rate and relapse incidencewere significantly better
in thematched unrelated PBSCTgroup (P-value5 0.047, P-value5
0.039, respectively). In conclusion, the alloPBSCT outcomes for
AML were comparable in the matched related and matched unre-
lated groups. Nonetheless, for high-risk AML patients, matched un-
related PBSCT was found to be preferable to matched related
PBSCT.372
STAT3 PROMOTES BOTH NATURAL AND INDUCIBLE T REGULATORY
CELL PLASTICITY DURING MURINE ACUTE GVHD
Amarnath, S.1, Laurence, A.D.2, Mariotti, J.1, Foley, J.E.1,
O’Shea, J.J.2, Fowler, D.H.1 1CCR, NCI, Bethesda, MD; 2NIH,
Bethesda, MD
Adoptive cell transfer of FoxP3+ regulatory T cells (Tregs) has
been proposed as a novel therapy for prevention of acute GVHD.
Such therapy may theoretically be limited by conversion of Tregs
into pathological effector T cells due to STAT3-activating inflam-
matory cytokines, including IL-6, IL-21, and IL-23. To better un-
derstand the role of STAT3 in Treg cell plasticity during acute
GVHD, we used a B6 0 BALB/c transplantation model. Donor
cell populations were obtained from either, STAT3 fl/fl Foxp3-
GFP (WT) or CD4-Cre, STAT3 fl/fl-Foxp3 GFP (KO). Transfer
of T cell-replete, WT inocula uniformly resulted in lethality by
day 14 post-BMT; in contrast, T cell-replete, STAT3-KO recipients
had 100% post-BMT survival (p\ 0.001). Relative to WT recipi-
ents, STAT3-KO recipients also had less GVHD by histology as-
sessment (p\ 0.05) and had increased numbers of splenic FoxP3+
T cells post-BMT (p 5 0.005); in contrast, WT recipients had in-
creased IL-17 and IFN-g secreting T cells post-BMT (each, p\
0.01). The increased number of post-BMT FoxP3+ cells in
STAT3-KO recipients may have been due to: (1) increase in ‘‘in-
duced’’ Tregs from the na€ıve T cell pool; and (2) decrease in loss
of ‘‘natural’’ (n)Tregs. Purified, na€ıve, FoxP3 negative T cells from
WT or STAT3KO donors were transferred to evaluate the first pos-
sibility: after allogeneic BMT, FoxP3 induction was greatly in-
creased in STAT3-KO recipients relative to WT recipients (p \
0.01). And, to address the second possibility, purified WT and
STAT3-KO FoxP3+ Tregs were co-infused with conventional do-
nor T cells: relative to recipients of WT nTregs, recipients of
STAT3-KO nTregs had greatly increased post-BMT numbers of
FoxP3 post-BMT (p\0.05). As such, the in vivo pool of Treg cells
after allogeneic BMT is controlled to a great extent by STAT3 sig-
naling, which influences both natural and induced Treg pathways.373
IMPACT OF REDUCTION IN GVHD-RELATED MORTALITY FOR RECENT
IMPROVEMENT OF NON-RELAPSE MORTALITY AFTER ALLOGENEIC HE-
MATOPOIETIC CELL TRANSPLANTATION
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Purpose: We retrospectively assessed changes in the incidence and
causes of non-relapse mortality (NRM) over the last 12 years in
allo-HCT patients.
Methods:We analyzed a nationwide registry database that includes
patients aged 16 years or older with AML or ALL in remission, or
low-risk MDS who received allo-HCT from 1997 to 2008. We
compared the incidence of NRM and overall survival (OS) after
allo-HCT in three consecutive four-year periods (1997-2000,
2001-2004, and 2005-2008) for younger patients (16-49 years), and
in the later two periods for older patients ($ 50 years). Subgroup
analyses were performed based on patient age and donor source:
HLA-matched/1-Ag mismatched related donor (related donor)
versus unrelated BM or CB donor (alternative donor).
Results: A total of 6517 patients with a median age of 40 years were
analyzed and the median follow-up was 39 months. A total of 1354,
2298, and 2865 allo-HCT were performed in 1997-2000, 2001-
2004, and 2005-2008, respectively. The incidence of NRM was
23% at 3 years after allo-HCT. A subgroup analysis of younger pa-
tients who received allo-HCT from a related donor showed that
there was no significant change in NRM (12-15%). In younger pa-
tients who received allo-HCT from an alternative donor, the
Poster Session II S289NRM incidence significantly decreased over the three periods (30%,
24%, and 22%, p\0.001) mainly due to a reduced risk of death as-
sociated with organ failure (14%, 9%, and 7%, p 5 0.005) and
GVHD (7%, 3%, and 3%, p\ 0.001), which led to a significantly
improved OS (58%, 59%, and 64%, p 5 0.008). In older patients
who received allo-HCT from a related donor, NRM significantly
improved in 2005-2008 compared to 2001-2004 (29% vs 18%, p
\0.001) due to a reduced risk of death associated with organ failure
(11% vs 6%, p5 0.007) andGVHD (6% vs 3%, p5 0.11). However,
due to the increase in the incidence of relapse in 2005-2008, this
decreased NRM did not lead to an improvement of OS (51% vs
55%, p 5 0.21). In older patients who received allo-HCT from an
alternative donor, NRM and OS significantly improved in 2005-
2008 compared to 2001-2004 (NRM, 43% vs 31%; OS, 40% vs
51%, p\ 0.001). The reduction in NRM was mainly due to a de-
crease in death associated with infection (17% vs 11%, p 5 0.007)
and GVHD (7% vs 4%, p 5 0.152).
Conclusions: NRM and OS have recently improved, especially for
allo-HCT from unrelated BM or CB donors. These advances
seemed to be due to a reduced risk of death associated with
GVHD in both younger and older patients.374
OLDER SIBLING DONORS REMAIN AN EXCELLENT OPTION: OLDER
DONOR AGE AND LOWER CD34 INFUSED DO NOT ADVERSELY IMPACT
OUTCOMES FOR MATCHED SIBLING PERIPHERAL BLOOD STEM CELL
(PBSC) TRANSPLANTATION
Richa, E.1,Martinez, G.2, Kunnavakkam, R.3,Wickrema, A.2, Allen, J.2,
Thomas, R.2, van Besien, K.2, Artz, A.2 1University of Chicago Medical
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Intro: For unrelated donor allografts, higher cell doses improve out-
comes. Increasingly, older patient age is prompting consideration of
older sibling donors. On average, older donors mobilize PBSC less
well.We hypothesized that outcomes would be worse after older sib-
ling PBSC allografts as older age adversely impacts PBSC yields.
Methods:We reviewed transplant outcomes fromHLAmatched or
single antigen/allele mismatched siblings harvested between January
2001 and April 2008. Donors underwent uniform PBSC mobiliza-
tion of G-CSF at 10 mcg/kg/day and apheresis on day 5. We evalu-
ated the influence donor and recipient age as continuous variables.
We also explore the allograft dose by CD34 dose infused above
the median and the peripheral blood (PB) CD34 on day 5 pre-apher-
esis (a biologic measure of mobilization capacity of the donor). All
diseases and conditioning regimens were included. The majority of
patients underwent regimens incorporating campath.
Results: Of the 195 sibling donors who underwent mobilization,
182 pts (93%) were infused with PBSCs from one mobilization at-
tempt. The median donor age was 52 years (range 16-70) and
16.9% were 60 years or older. Median recipient age was 53.2 years.
The median CD34 infused was 5.4 x10(6)/kg (range 0.34 to 13.2).
The risk of acute II-IV GVHD did not correlate with older donor
age (HR 5 1.01, P0.49), recipient age (HR 5 1.04, 95%CI, 0.99-
1.09; P 5 0.06), CD34 infused above the median (HR 5 1.19, P 5
0.12), or higher pre-apheresis PB CD34 (HR 5 1.01, P 5 0.82).
However, only 22 recipients developed aGVHD. Donor age was
not associated with relapse free survival (RFS) (HR 5 1.06, P 5
0.45) or OS (HR 5 1.06, P 5 0.53). Older recipients, however,
had inferior OS (HR 5 1.02, P 5 0.014) but not RFS (HR 5 1.01,
P 5 0.30). OS was not associated with peak PB pre-apheresis
CD34 (P 5 0.73) or CD34 infused (P 5 0.85). In multivariate anal-
ysis of donor age, recipient age, disease status and CD34 infused,
higher CD34 infused did not impact OS. While older recipient
age demonstrated a strong association with poorer OS (P 5 .008),
older donor age showed a borderline associated with improved OS
(PS 5 .049).
Conclusion: After adjusting for recipient age and disease, lower
CD34 infused and older donor age had no detrimental impact on
GVHD, relapse, or OS. Absent data showing a benefit of younger
unrelated donors, we conclude that medically cleared older sibiling
donors should be considered the standard of care when available,
at least up to age 70 years.375
ALEMTUZUMAB VS ATG FOR T-CELL DEPLETION IN SIBLING DONOR RE-
DUCED INTENSITY HAEMATOPOIETIC STEM CELL TRANSPLANTATION
(RIC HSCT) FOR THE TREATMENT OF ACUTE MYELOID LEUKAEMIA
AND MYELODYSPLASTIC SYNDROME
Potter, V.T., Tindell, V.J., Reiff-Zall, L., Ho, A., Kenyon, M., Marsh, J.,
Pagliuca, A.,Mufti, G.J., Lim, Z. Kings College Hospital, London, United
Kingdom
We report the results of a retrospective analysis on 83 patients who
underwentHLA-matched sibling donor RICHSCT receiving either
ATG or alemtuzumab. All patients received a uniform protocol of
fludarabine and busulfan. For T-cell depletion/GVHD prophylaxis
48 patients received alemtuzumab(20mg x 5 days IV) followed by
cyclosporin A post-transplant. 35 patients received ATG(Thymo-
globulin, Genzyme)(total 6mg/kg over 3 days IV) followed by meth-
otrexate/cyclosporine A post-transplant.
Diagnoses included myelodysplastic syndrome (MDS)(n 5 34),
acute myeloid leukaemia (AML)(n 5 40) or MDS/MPD(n 5 9).
Median recipient age was 56yrs(range 22-72) in both groups. All pa-
tients received PBSC with median CD34 cell dose of 5.06 x106/kg.
There were no significant differences between groups with regard
to age, disease type, cytogenetic risk, disease stage at transplantation,
or CD34 cell dose. Median follow-up (for survivors) was 743 days
(range 31-1516) for ATG and 2193 days (range: 39-3595) for
alemtuzumab.
Median time to neutrophil (0.5x10^9/L) regeneration was 14 days
in both groups. There were 3 primary graft failures (1 ATG, 2 alem-
tuzumab).Median donor CD3 chimerism to day 100(alemtuzumab v
ATG) was 73% v 65% at D30, 74% v 69.5% at D60 and 67% v 44%
at D100(p5NS). A higher proportion of patients receiving alemtu-
zumab required subsequent DLI therapy (68.8 v 31.4% p 5 0.001).
The main reason for DLI in each group was falling donor chimerism
(61 v 57.1%p5NS). The incidence of de novo cGVHD was higher
in the ATG arm(25.6 v 8.3% p 5 0.06), however this was offset by
subsequent development of cGVHD in the alemtuzumab arm due
to greater DLI administration. Consequently overall rates of chronic
GVHDwere similar between alemtuzumab and ATG arms(41.2% v
40%). The 2-year OS in the ATG v alemtuzumab group was 67.8
+/2 8.5% vs 50.3 +/2 7.4%(p 5 0.38). DFS was 51 +/2 9.4% in
ATG patients, vs 38.3 +/27.1% in alemtuzumab patients. There
was no significant difference in TRMor relapse between the alemtu-
zumab vs ATG group 27+/27.5% v 15+/26.9%, (p 5 0.48), and
47.5+/27.8% vs 43.8 +/2 9.8%.
In summary, our experience indicates that in patients with MDS/
AML having sibling donor RIC HSCT, use of ATG results in com-
parable outcomes when compared with alemtuzumab, with signifi-
cantly lower need for DLI. While the incidence of GvHD is
similar between groups, ATG patients are more likely to develop
de novo GvHD when compared with alemtuzumab patients who
develop delayed GvHD following DLI.376
SILICA-INDUCED IMPAIRMENT OF MACROPHAGE FUNCTION REDUCES
GVHD SEVERITY AND IMPROVES SURVIVAL
Sega, E.I., Leveson-Gower, D.B., Negrin, R.S. Stanford University,
Stanford, CA
Acute graft versus host disease (GVHD) is a major complication of
bonemarrow transplantation (BMT). The pathogenesis of GVHD is
characterized by a cascade of inflammatory cytokines and effector
molecules that maintain a proinflammatorymilieu capable of contin-
uously activating immune cells leading to tissue injury. Several stud-
ies have demonstrated a role for macrophages in secreting these
proinflammatory mediators during GVHD progression. Silica
decreases the phagocytic capacity of macrophages and alters their ca-
pacity to activate T cells by switching from a Th1 to a Th2 response.
Therefore, we investigate whether altering macrophage function by
in vivo administration of silica would result in alleviation of GVHD
symptoms and improved survival. Mice were lethally irradiated and
transplanted with with 5x106 allogeneic T-cell depleted bone mar-
row cells (TCD-BM) and 7.5x105 allogeneic conventional T cells
(Tcon) to induce GVHD. A significant increase in median survival
